{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T11:24:35Z","timestamp":1787397875869,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04319-3","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T07:40:16Z","timestamp":1773992416000},"page":"4225-4235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ultra-rare TP53 and KRAS variants predict survival in ICI-treated solid tumours"],"prefix":"10.1007","volume":"28","author":[{"given":"Vicente Javier","family":"Clemente-Su\u00e1rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Olivares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9311-6576","authenticated-orcid":false,"given":"Rodrigo","family":"Y\u00e1\u00f1ez-Sep\u00falveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Guzm\u00e1n-Mu\u00f1\u00f3z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra Mart\u00edn","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"4319_CR1","doi-asserted-by":"publisher","unstructured":"Zhang Y, Barkdull S, Kontoyiannis PD, Flores Legarreta A, Gershenson DM, Ramalingam P, et al., et al. TP53 and KRAS co-mutations are associated with worse outcomes in mucinous ovarian carcinomas. Front Oncol. 2025;15:1573801. https:\/\/doi.org\/10.3389\/fonc.2025.1573801.","DOI":"10.3389\/fonc.2025.1573801"},{"key":"4319_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.532403","volume":"10","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Fu Q, Bai X, Liang T. Molecular profiling\u2013based precision medicine in cancer: a review of current evidence and challenges. Front Oncol. 2020;10:532403. https:\/\/doi.org\/10.3389\/fonc.2020.532403.","journal-title":"Front Oncol"},{"issue":"suppl 1","key":"4319_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35783","volume":"131","author":"K Shaverdashvili","year":"2025","unstructured":"Shaverdashvili K, Burns TF. Advances in the treatment of KRAS G12C mutant non\u2013small cell lung cancer. Cancer. 2025;131(suppl 1):e35783. https:\/\/doi.org\/10.1002\/cncr.35783.","journal-title":"Cancer"},{"key":"4319_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43018-025-01077-z","volume":"6","author":"S Misale","year":"2025","unstructured":"Misale S. The evolving landscape of RAS-targeted therapies. Nat Cancer. 2025;6:1\u20133. https:\/\/doi.org\/10.1038\/s43018-025-01077-z.","journal-title":"Nat Cancer"},{"key":"4319_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.lungcan.2019.04.005","volume":"132","author":"S Assoun","year":"2019","unstructured":"Assoun S, Theou-Anton N, Nguenang M, Cazes A, Danel C, Abbar B, et al. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. Lung Cancer. 2019;132:65\u201371. https:\/\/doi.org\/10.1016\/j.lungcan.2019.04.005.","journal-title":"Lung Cancer"},{"issue":"14","key":"4319_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cells13141221","volume":"13","author":"K Mondal","year":"2024","unstructured":"Mondal K, Posa MK, Shenoy RP, Roychoudhury S. KRAS mutation subtypes and their association with other driver mutations in oncogenic pathways. Cells. 2024;13(14):1221. https:\/\/doi.org\/10.3390\/cells13141221.","journal-title":"Cells"},{"issue":"9","key":"4319_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","volume":"19","author":"F Skoulidis","year":"2019","unstructured":"Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19(9):495\u2013509. https:\/\/doi.org\/10.1038\/s41568-019-0179-8.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4319_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01166-3","volume":"9","author":"M Navarro-Jim\u00e9nez","year":"2025","unstructured":"Navarro-Jim\u00e9nez M, Gonz\u00e1lez B, Mulet N, Hierro C, Alonso S. KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials. NPJ Precis Oncol. 2025;9(1):380. https:\/\/doi.org\/10.1038\/s41698-025-01166-3.","journal-title":"NPJ Precis Oncol"},{"key":"4319_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.lungcan.2019.04.005","volume":"132","author":"M Nguenang","year":"2019","unstructured":"Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2017;23(12):3012-3024. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2554.","journal-title":"Lung Cancer"},{"issue":"5","key":"4319_CR10","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","volume":"28","author":"LA Donehower","year":"2019","unstructured":"Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M,\u00a0et al. Integrated analysis of TP53 gene and pathway alterations in The Cancer Genome Atlas. Cell Rep. 2019;28(5):1370-1384.e5. https:\/\/doi.org\/10.1016\/j.celrep.2019.07.001.","journal-title":"Cell Rep"},{"issue":"1","key":"4319_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/1073274820976665","volume":"27","author":"Q Lyu","year":"2020","unstructured":"Lyu Q, Lin A, Cao M, Xu A, Luo P, Zhang J. Alterations in TP53 are a potential biomarker of bladder cancer patients who benefit from immune checkpoint inhibition. Cancer Control. 2020;27(1):1073274820976665. https:\/\/doi.org\/10.1177\/1073274820976665.","journal-title":"Cancer Control"},{"issue":"1","key":"4319_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01955-5","volume":"9","author":"Z Liu","year":"2024","unstructured":"Liu Z, Chen J, Ren Y, Liu S, Ba Y, Zuo A,\u00a0et al. Multi-stage mechanisms of tumor metastasis and therapeutic strategies. Signal Transduct Target Ther. 2024;9(1):270. https:\/\/doi.org\/10.1038\/s41392-024-01955-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"4319_CR13","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.cell.2017.09.042","volume":"171","author":"I Martincorena","year":"2017","unstructured":"Martincorena I, Raine KM, Gerstung M, Dawson KJ, Haase K, Van Loo P, et al. Universal patterns of selection in cancer and somatic tissues. Cell. 2017;171(5):1029-1041.e21. https:\/\/doi.org\/10.1016\/j.cell.2017.09.042.","journal-title":"Cell"},{"issue":"3","key":"4319_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41416-024-02746-z","volume":"131","author":"J Budczies","year":"2024","unstructured":"Budczies J, Romanovsky E, Kirchner M, et al. KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma. Br J Cancer. 2024;131(3):524\u201333. https:\/\/doi.org\/10.1038\/s41416-024-02746-z.","journal-title":"Br J Cancer"},{"key":"4319_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116058","volume":"171","author":"M Xu","year":"2024","unstructured":"Xu M, Zhao X, Wen T, Qu X. Unveiling the role of KRAS in tumor immune microenvironment. Biomed Pharmacother. 2024;171:116058. https:\/\/doi.org\/10.1016\/j.biopha.2023.116058.","journal-title":"Biomed Pharmacother"},{"key":"4319_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19288-6","volume":"11","author":"S Hamarsheh","year":"2020","unstructured":"Hamarsheh S, Larnicol A. Immune modulatory effects of oncogenic KRAS in cancer. Nat Commun. 2020;11:5439. https:\/\/doi.org\/10.1038\/s41467-020-19288-6.","journal-title":"Nat Commun"},{"key":"4319_CR17","doi-asserted-by":"publisher","unstructured":"Yang Y, Zhuo Z, Liu C, Su M, Zhao X, Li X. TP53 co-mutations are associated with elevated PD-L1 expression and high tumor mutational burden in non-small cell lung cancer: insights from comprehensive genomic profiling. Transl Lung Cancer Res. 2026;15(1):10. https:\/\/doi.org\/10.21037\/tlcr-2025-1030.","DOI":"10.21037\/tlcr-2025-1030"},{"issue":"8","key":"4319_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","volume":"19","author":"AR Moore","year":"2020","unstructured":"Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020;19(8):533\u201352. https:\/\/doi.org\/10.1038\/s41573-020-0068-6.","journal-title":"Nat Rev Drug Discov"},{"key":"4319_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-01785-9","author":"B Kinnersley","year":"2024","unstructured":"Kinnersley B, Sud A, Everall A, Cornish AJ, Chubb D, Culliford R, et al. Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology. Nat Genet. 2024. https:\/\/doi.org\/10.1038\/s41588-024-01785-9.","journal-title":"Nat Genet"},{"issue":"6","key":"4319_CR20","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703\u201313. https:\/\/doi.org\/10.1038\/nm.4333.","journal-title":"Nat Med"},{"issue":"7484","key":"4319_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495\u2013501. https:\/\/doi.org\/10.1038\/nature12912.","journal-title":"Nature"},{"issue":"269","key":"4319_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. https:\/\/doi.org\/10.1126\/scisignal.2004088.","journal-title":"Sci Signal"},{"issue":"2","key":"4319_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY,\u00a0et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u20136. https:\/\/doi.org\/10.1038\/s41588-018-0312-8.","journal-title":"Nat Genet"},{"issue":"22","key":"4319_CR24","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C,\u00a0et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1801946.","journal-title":"N Engl J Med"},{"issue":"6230","key":"4319_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138. https:\/\/doi.org\/10.1126\/science.aaa1348.","journal-title":"Science"},{"issue":"8","key":"4319_CR26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","volume":"5","author":"F Skoulidis","year":"2015","unstructured":"Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015;5(8):860\u201377. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-1236.","journal-title":"Cancer Discov"},{"issue":"1","key":"4319_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R,\u00a0et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. https:\/\/doi.org\/10.1186\/s13073-017-0424-2.","journal-title":"Genome Med"},{"issue":"10","key":"4319_CR28","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/2767-9764.CRC-25-0188","volume":"5","author":"S Park","year":"2025","unstructured":"Park S, Ikegami M, Kitada R, Takamochi K, Suzuki K, Mano H, et al. Functional analysis of rare RAS variants of unknown significance. Cancer Res Commun. 2025;5(10):1747\u201357. https:\/\/doi.org\/10.1158\/2767-9764.CRC-25-0188.","journal-title":"Cancer Res Commun"},{"issue":"5","key":"4319_CR29","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","volume":"28","author":"A Korkut","year":"2019","unstructured":"Ho TLF, Lee MY, Goh HC, Ng GYN, Lee JJH, Kannan S, et al. Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities. Nat Commun. 2023;14(1):1726. https:\/\/doi.org\/10.1038\/s41467-023-37223-3.","journal-title":"Cell Rep"},{"issue":"25","key":"4319_CR30","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J,\u00a0et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371\u201381. https:\/\/doi.org\/10.1056\/NEJMoa2103695.","journal-title":"N Engl J Med"},{"key":"4319_CR31","doi-asserted-by":"publisher","unstructured":"Jiang Y, Mai G, Zhao X, et al. Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: insights from multi-cohort analysis. NPJ Precis Oncol. 2025;9(1):299.  https:\/\/doi.org\/10.1038\/s41698-025-01087-1","DOI":"10.1038\/s41698-025-01087-1"},{"key":"4319_CR32","doi-asserted-by":"publisher","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI,\u00a0et al. KRAS G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1917239.","DOI":"10.1056\/NEJMoa1917239"},{"key":"4319_CR33","doi-asserted-by":"crossref","unstructured":"Frost N, Kollmeier J, Vollbrecht C, Grah C, Matthes B, Pultermann D,\u00a0et al. KRAS G12C\/TP53 co-mutations identify long-term responders to pembrolizumab monotherapy in lung adenocarcinoma. Transl Lung Cancer Res. 2021;10(2):574\u201382.","DOI":"10.21037\/tlcr-20-958"},{"issue":"1","key":"4319_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S,\u00a0et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4\u201323. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.10.002.","journal-title":"J Mol Diagn"},{"key":"4319_CR35","doi-asserted-by":"publisher","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N,\u00a0et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941\u20137. https:\/\/doi.org\/10.1093\/nar\/gky1015.","DOI":"10.1093\/nar\/gky1015"},{"issue":"2","key":"4319_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/sj.bjc.6601894","volume":"91","author":"S Bamford","year":"2004","unstructured":"Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A,\u00a0et al. The COSMIC (catalogue of somatic mutations in cancer) database and website. Br J Cancer. 2004;91(2):355\u20138. https:\/\/doi.org\/10.1038\/sj.bjc.6601894.","journal-title":"Br J Cancer"},{"key":"4319_CR37","doi-asserted-by":"publisher","unstructured":"Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discov. 2020;10(12):1808\u201325.  https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0522","DOI":"10.1158\/2159-8290.CD-20-0522"},{"issue":"25","key":"4319_CR38","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"GK Dy","year":"2021","unstructured":"J\u00e4nne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SHI, Pacheco JM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS G12C Mutation. N Engl J Med. 2022;387(2):120-131. https:\/\/doi.org\/10.1056\/NEJMoa2204619.","journal-title":"N Engl J Med"},{"key":"4319_CR39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00046","author":"MV Negrao","year":"2023","unstructured":"Negrao MV, Spira AI, Heist RS, J\u00e4nne PA, Pacheco JM, Weiss J,\u00a0et al. Intracranial efficacy of adagrasib in patients from the KRYSTAL-1 trial with KRAS G12C\u2013mutated non\u2013small-cell lung cancer and untreated CNS metastases. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/JCO.23.00046.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4319_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12554-6","volume":"24","author":"T Yamaguchi","year":"2024","unstructured":"Yamaguchi T, Shimizu J, Matsuzawa R, Watanabe N, Horio Y, Fujiwara Y. Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis. BMC Cancer. 2024;24(1):842. https:\/\/doi.org\/10.1186\/s12885-024-12554-6.","journal-title":"BMC Cancer"},{"issue":"9","key":"4319_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","volume":"19","author":"JV Heymach","year":"2019","unstructured":"Nishikawa S, Iwakuma T. Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials. Cancers (Basel). 2023;15(2):429. https:\/\/doi.org\/10.3390\/cancers15020429.","journal-title":"Nat Rev Cancer"},{"key":"4319_CR42","doi-asserted-by":"publisher","unstructured":"Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12(1):8. https:\/\/doi.org\/10.1186\/s13073-019-0703-1","DOI":"10.1186\/s13073-019-0703-1"},{"key":"4319_CR43","doi-asserted-by":"publisher","unstructured":"Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017;2017:PO.17.00011. https:\/\/doi.org\/10.1200\/PO.17.00011.","DOI":"10.1200\/PO.17.00011"}],"updated-by":[{"DOI":"10.1007\/s12094-026-04379-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000}}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04319-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T11:04:44Z","timestamp":1787396684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04319-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["4319"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04319-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: to correct the graphics relating to Figs. 1, 2 and 3 captions and References 17, 31, 37 and 42.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12094-026-04379-5","URL":"https:\/\/doi.org\/10.1007\/s12094-026-04379-5","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study utilised publicly available, de-identified data from the Memorial Sloan Kettering Cancer Center (MSKCC) MSK-IMPACT cohort accessed via cBioPortal. As such, it qualifies as secondary research on existing data and does not involve human subjects directly. The original data collection complied with the Declaration of Helsinki, institutional review board approvals, and informed consent procedures as reported by MSKCC. No additional ethical approval was required for this retrospective analysis.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient consent was waived due to the retrospective nature of the study and the use of fully anonymized data.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as no individual patient data or identifiable information is presented.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}